EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Insights from changes in NDEV biomarkers of metabolism: effects of PPARγ and GLP1 receptor agonists on brain metabolism

Audrey Evers iD, Kathleen Watson, Fahim Abbasi, Kashfia Haque, Ajay Verma, Erez Eitan, Natalie Rasgon iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag176 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Audrey Evers und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Brain. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, American Diabetes Association, NIMH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Insulin resistance (IR) is implicated in central nervous system disorders, including depression and Alzheimer's disease (AD).

Methods

We analyzed biological samples from two cohorts of clinical trial participants: (1) participants with unremitted depression after six months of treatment as usual who received pioglitazone (PPARγ agonist, N = 12) or placebo and (2) middle-aged participants at genetic risk for AD who received liraglutide (glucagon-like peptide 1 [GLP1] receptor agonist, N = 15) or placebo. These cohorts, which previously showed treatment-related improvements in peripheral IR, were used to assess the effects of pioglitazone and liraglutide on CNS insulin signaling using neuron-derived extracellular vesicles (NDEVs) as biomarkers. We utilized biological samples to measure biomarkers of IR in NDEVs. Eleven Akt-mTOR pathway proteins were measured before and after 12 weeks of treatment in both groups.

Results

Participants who received pioglitazone experienced broader changes, with significant increases in GSK3β (Ser9), mTOR (Ser2448), and RPS6 (Ser235/Ser236; all P ≤ .02) compared with placebo, and 77% of participants showed mTOR (Ser2448) response. Participants who received liraglutide demonstrated significantly increased NDEV-associated phosphorylated Akt (Ser473) and mTOR (Ser2448; P = .04 and P = .025, respectively) compared with placebo, with 40% and 30% of participants in the liraglutide group showing biomarker response in both Akt (Ser473) and mTOR (Ser2448), respectively. These effects appeared relatively independent from changes in fasting plasma insulin and glucose concentration at 120-minutes during the oral glucose tolerance test.

Discussion

Our findings demonstrate CNS-specific biomarker responses to both PPARγ agonists and GLP1 receptor agonists.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsBrainHumansPioglitazonePPAR-gamma AgonistsBiomarkersFemaleLiraglutideMaleInsulin ResistanceMiddle AgedPPAR gammaHypoglycemic AgentsAlzheimer DiseaseAgedNeuronsSignal Transduction

Stichwörter der Autor:innen

Akt–mTOR signalingCNS insulin resistancedepressive disorder and neurodegenerationliraglutide (GLP-1 receptor agonist)neuron-derived extracellular vesicles (NDEVs)pioglitazone (PPARγ agonist)

Substanzen

PioglitazonePPAR-gamma AgonistsBiomarkersLiraglutideGlucagon-Like Peptide-1 Receptor AgonistsPPAR gammaHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • NeuroDex Inc., Natick, MA, USA.

ORCID-Profile: Audrey Evers, Natalie Rasgon

Förderung

  • NIMH NIH HHS
  • American Diabetes Association
  • NIMH

Zitieren

APA

Evers, A., Watson, K., Abbasi, F., Haque, K., Verma, A., Eitan, E., & Rasgon, N. (2026). Insights from changes in NDEV biomarkers of metabolism: effects of PPARγ and GLP1 receptor agonists on brain metabolism. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag176

Vancouver

Evers A, Watson K, Abbasi F, Haque K, Verma A, Eitan E, et al. Insights from changes in NDEV biomarkers of metabolism: effects of PPARγ and GLP1 receptor agonists on brain metabolism. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag176

BibTeX
@article{Evers2026,
  author = {Evers, Audrey and Watson, Kathleen and Abbasi, Fahim and Haque, Kashfia and Verma, Ajay and Eitan, Erez and Rasgon, Natalie},
  title = {Insights from changes in NDEV biomarkers of metabolism: effects of PPARγ and GLP1 receptor agonists on brain metabolism},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag176}
}
Kostenlos starten →